KALA BIO Inc
kalarx.comWhat Do They Do?
Develops an on-premises AI platform for biotechnology and pharmaceutical companies and seeks third-party deals for its biologics assets.
10-K for FY2025, filed Apr 15, 2026Our current activities comprise of (i) evaluating strategic alternatives for our legacy MSC-S assets and related intellectual property and…View ↗
Preserve and seek to monetize our MSC-S biologics asset portfolio. We are preserving our MSC-S platform intellectual property, including…View ↗
Develop and aim to deploy Researgency as a dedicated biotechnology industry solution. Through our exclusive license for Researgency, we…View ↗
Who Are Their Customers?
The planned AI platform is aimed at biotechnology and pharmaceutical companies, contract research organizations, and academic research institutions. The company plans to sell directly and supplement those efforts with partners and channel arrangements.
10-K for FY2025, filed Apr 15, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 19, 2026
−$1.6MView ↗
- ▼ −86% (Loss)
- vs −$11.2M in Q2 FY2025
-
Sep 3, 2026
Virotek appointed KALA distributor for ophthalmology genetic testing
The agreement makes KALA the sole U.S. distributor if it meets a milestone; KALA handles commercial development while Virotek delivers the program.
Sources
8-K, filed Sep 10, 2026
Pursuant to the Agreement, Virotek has appointed Kala as the sole and exclusive distributor and reseller of a genetic testing and screening…View ↗
-
Aug 28, 2026
Nasdaq found the company out of compliance with its bid-price rule
The company said it would request a hearing; a timely request would pause suspension or delisting while the panel decides.
Sources
8-K, filed Aug 28, 2026
On August 27, 2026, KALA BIO, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications…View ↗
From eye therapies to biotech AI
The earlier report centered on clinical development of therapies for eye diseases, including a lead candidate and a related preclinical program. The latest report says development of the lead candidate and stem-cell platform has stopped, while the company evaluates an on-premises AI platform and seeks deals for its biologics assets.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Apr 15, 2026On September 28, 2025, the board of directors of the Company (the “Board”) determined to cease development of KPI-012 and the MSC-S…View ↗
Our current activities comprise of (i) evaluating strategic alternatives for our legacy MSC-S assets and related intellectual property and…View ↗
Preserve and seek to monetize our MSC-S biologics asset portfolio. We are preserving our MSC-S platform intellectual property, including…View ↗
Develop and aim to deploy Researgency as a dedicated biotechnology industry solution. Through our exclusive license for Researgency, we…View ↗
Loading...
